Musli Thyropeutics is a pharmaceutical innovator addressing high-grade cancers. The company's scientists have developed a unique treatment based on recent scientific findings which deprives these aggressive cancers from a much needed hormone.
Musli is targeting Glioblastoma Multiforme as well as brain metastases from lung and other cancers and other aggressive high-grade cancers.
Musli is well poised to fulfil the unmet needs of several multi-billion dollar markets by providing an innovative adjunct approach to current standard of care.
Musli has a solid patent portfolio and worldwide exclusive marketing rights.
Musli has partnered with a leading manufacturer to secure high-quality GMP manufacturing.